Erste Group Bank Cuts Earnings Estimates for Novartis

Novartis AG (NYSE:NVS) – Investment analysts at Erste Group Bank lowered their FY2026 earnings per share estimates for Novartis in a note issued to investors on Wednesday, October 21st. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings per share of $9.16 for the year, down from their prior forecast of $9.24. The consensus estimate for Novartis’ current full-year earnings is $8.91 per share. Erste Group Bank also issued estimates for Novartis’ FY2027 earnings at $9.81 EPS.

Several other equities analysts have also recently weighed in on NVS. HSBC raised shares of Novartis from a “reduce” rating to a “hold” rating and raised their price target for the stock from $123.00 to $136.00 in a research note on Thursday, September 10th. UBS Group reiterated a “neutral” rating on shares of Novartis in a report on Wednesday. Citigroup reissued a “buy” rating on shares of Novartis in a research report on Wednesday, July 22nd. The Goldman Sachs Group restated a “sell” rating on shares of Novartis in a research note on Monday, September 21st. Finally, JPMorgan Chase & Co. reissued a “buy” rating on shares of Novartis in a report on Sunday, August 9th. Six research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Novartis has a consensus rating of “Hold” and a consensus target price of $145.60.

Novartis Trading Up 1.9%

NYSE:NVS opened at $156.81 on Wednesday. Novartis has a 52-week low of $121.57 and a 52-week high of $170.46. The stock has a 50-day simple moving average of $148.28 and a 200 day simple moving average of $151.54.

Novartis (NYSE:NVS) last posted its quarterly earnings data on Tuesday, October 27th. The company reported $2.46 EPS for the quarter, beating the consensus estimate of $2.25 by $0.21. The company had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.53 billion. The company’s revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.25 earnings per share.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in NVS. WCM Investment Management LLC bought a new stake in shares of Novartis during the 1st quarter worth about $220,004,000. Bank of America Corp DE lifted its position in Novartis by 9.1% during the first quarter. Bank of America Corp DE now owns 4,962,794 shares of the company’s stock worth $758,067,000 after acquiring an additional 413,778 shares during the last quarter. Miller Howard Investments Inc. NY bought a new stake in shares of Novartis during the third quarter worth approximately $32,737,000. Ferguson Wellman Capital Management Inc. bought a new stake in shares of Novartis during the first quarter worth approximately $27,855,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Novartis by 40.4% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 195,986 shares of the company’s stock worth $30,715,000 after purchasing an additional 56,424 shares during the period. 13.12% of the stock is currently owned by institutional investors.

Trending Headlines about Novartis

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Novartis reported third-quarter EPS of $2.46, above the $2.25 analyst consensus, while revenue reached approximately $15.03 billion versus expectations of $14.53 billion. Sales increased 4.4% year over year. Novartis quarterly earnings report
• Positive Sentiment: The company raised its 2026 core operating-income outlook, citing productivity gains and continued demand for newer medicines. Novartis maintained its sales-growth forecast as Kisqali, Kesimpta and Scemblix helped offset generic competition. Novartis Q3 earnings and outlook
• Positive Sentiment: Phase 3 data for remibrutinib in multiple sclerosis showed lower relapse rates, with no Hy’s Law liver-safety cases reported, supporting the potential of the company’s development pipeline. Remibrutinib multiple sclerosis trial results
• Neutral Sentiment: NVS has moved above its 200-day moving average, a technical signal that may reinforce bullish sentiment, although it does not change the company’s fundamentals. Novartis shares cross above 200-day moving average
• Negative Sentiment: Reported profit declined because of a roughly $1.9 billion impairment charge, higher expenses and setbacks in recent clinical trials. Investors are also monitoring Kisqali, Novartis’ largest revenue contributor, which fell short of expectations. Novartis earnings caveats

Novartis Company Profile

Novartis AG is a Switzerland-based pharmaceutical company focused on the discovery, development and commercialization of innovative medicines. The company’s research and commercial activities span areas including cardiovascular, renal and metabolic diseases, immunology, neuroscience, oncology and hematology. Its portfolio includes prescription medicines such as Entresto, Cosentyx, Kisqali, Kesimpta, Leqvio, Pluvicto and Scemblix.

Novartis serves patients and healthcare providers in markets around the world.